山东步长制药股份有限公司 董事会薪酬与考核委员会工作细则 第一章 总 则 第一条 为进一步建立健全山东步长制药股份有限公司（以下简称公司）董事、高级 管理人员的考核和薪酬管理制度，完善公司治理结构，根据《中华人民共和国公司法》《上 市公司治理准则》《上市公司独立董事管理办法》《上海证券交易所股票上市规则》等法律、 行政法规和规范性文件以及《山东步长制药股份有限公司章程》（以下简称《公司章程》） 的有关规定，公司特设立董事会薪酬与考核委员会（以下称薪酬与考核委员会），并制定 本工作细则。 第二条 薪酬与考核委员会是董事会下设的专门工作机构，主要负责制定公司董事及 高级管理人员的考核标准并进行考核；负责制定、审查公司董事及高级管理人员的薪酬政 策与方案，对董事会负责。 第三条 本工作细则所称董事是指在本公司支取薪酬的董事长、董事，高级管理人员 是指董事会聘任的总裁、副总裁、董事会秘书、财务总监及由总裁提请董事会认定的其他 高级管理人员。 第二章 人员组成 山东步长制药股份有限公司 董事会薪酬与考核委员会工作细则 第七条 薪酬与考核委员会任期与董事会任期一致，委员任期届满，连选可以连任。 期间如有委员不再担任公司董 ...

山东步长制药股份有限公司 信息披露暂缓与豁免业务管理制度 第四条 公司应当审慎确定信息披露暂缓、豁免事项，履行内部审核程序 后实施。 山东步长制药股份有限公司 信息披露暂缓与豁免业务管理制度 第一章总则 第一条 为规范山东步长制药股份有限公司（以下简称公司）信息披露暂 缓与豁免行为，加强保密意识，维护公司利益，保护投资者合法权益，根据《中 华人民共和国证券法》（以下简称《证券法》）《上市公司信息披露暂缓与豁免 管理规定》《上海证券交易所股票上市规则》、《上海证券交易所上市公司自律 监管指引第 2 号——信息披露事务管理》等法律法规、规范性文件，制定本制度。 第二条 公司暂缓、豁免披露临时报告，在定期报告、临时报告中豁免披 露中国证券监督管理委员会（以下简称中国证监会）和上海证券交易所（以下简 称上交所）规定或者要求披露的内容，适用本制度。 第三条 公司应当真实、准确、完整、及时、公平地披露信息，不得滥用 暂缓或者豁免披露规避信息披露义务、误导投资者，不得实施内幕交易、操纵市 场等违法行为。 第二章暂缓、豁免披露信息的范围 第五条 公司有确实充分的证据证明拟披露的信息涉及国家秘密或者其 他因披露可能导致违反国家 ...

Core Viewpoint - The company has signed a distribution, marketing service, and agency agreement with Helios and Zaoan International for the exclusive marketing and distribution of injectable Efparepoetin alfa in targeted regions, which is a new Class I biopharmaceutical drug for treating anemia in adult dialysis patients due to chronic kidney disease (CKD) [1] Group 1 - The subsidiary Luzhou Buchang will authorize Helios to carry out exclusive marketing and distribution of injectable Efparepoetin alfa [1] - Injectable Efparepoetin alfa is intended for adult dialysis patients undergoing erythropoietin therapy due to anemia caused by chronic kidney disease [1] - The drug has already submitted a market application for approval [1]

Core Viewpoint - The company, Buchang Pharma, is expanding its market presence in Vietnam through a distribution agreement for its product Efparepoetin alfa, which is aimed at treating anemia in adult dialysis patients with chronic kidney disease [1] Company Summary - Buchang Pharma's subsidiary, Luzhou Buchang, plans to sign a distribution and marketing agreement with Helios and Aozan International in Vietnam [1] - Helios will act as the exclusive distributor in the region, while Aozan International will serve as an intermediary [1] - The product Efparepoetin alfa is specifically indicated for adult dialysis patients undergoing erythropoietin treatment due to anemia caused by chronic kidney disease [1] Financial Summary - In the third quarter of 2025, Buchang Pharma reported a net profit attributable to shareholders of 241 million yuan, representing a year-on-year increase of 195.44% [1]

Core Viewpoint - The company reported a decline in revenue for Q3 2025 while achieving significant growth in net profit compared to the previous year [1] Financial Performance - In Q3 2025, the company achieved an operating income of 2.805 billion yuan, a year-on-year decrease of 9.02% [1] - The net profit attributable to shareholders for Q3 2025 was 241 million yuan, reflecting a year-on-year increase of 195.44% [1] - Basic earnings per share for Q3 2025 were 0.2282 yuan [1] - For the first three quarters of 2025, the company reported an operating income of 8.469 billion yuan, a slight year-on-year decline of 0.54% [1] - The net profit attributable to shareholders for the first three quarters was 868 million yuan, showing a year-on-year increase of 177.54% [1] - Basic earnings per share for the first three quarters were 0.8208 yuan [1]

Core Insights - The traditional Chinese medicine sector saw a slight increase of 0.25% on October 29, with Jilin Aodong leading the gains [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Stock Performance - Jilin Aodong (000623) closed at 21.82, with a rise of 4.95% and a trading volume of 311,200 shares, amounting to a transaction value of 672 million yuan [1] - Other notable gainers included: - Biovale (920266) at 10.41, up 3.17% [1] - Datang Pharmaceutical (920433) at 6.74, up 2.90% [1] - Kang En Bei (600572) at 4.56, up 2.47% [1] - Baiyunshan (600332) at 26.12, up 2.15% [1] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 522 million yuan from institutional investors, while retail investors saw a net inflow of 560 million yuan [2][3] - The capital flow for key stocks showed: - Jilin Aodong had a net inflow of 75.01 million yuan from institutional investors [3] - Baiyunshan had a net inflow of 25.07 million yuan from institutional investors [3] - Zhenbao Island (603567) had a net inflow of 17.41 million yuan from institutional investors [3]

Core Viewpoint - The Shaanxi Provincial Government has awarded the first prize in the Science and Technology Progress Award for 2024 to a key technology integration demonstration application related to the quality assurance and low-carbon production of Qin medicine resources, led by Zhao Chao, the chairman and president of Shaanxi International Business and Trade Institute [1] Group 1 - Zhao Chao is a key contributor to the project that focuses on the standardization of the "Nao Xintong Capsule" under the National Administration of Traditional Chinese Medicine, emphasizing quality control from raw materials to finished products [1] - The project has established a comprehensive quality control technology system for the production of Nao Xintong Capsules, ensuring consistency across production batches [1] - Shaanxi International Business and Trade Institute was founded in 1997 by Buchang Pharmaceutical and is a full-time private undergraduate institution approved by the Ministry of Education [1]

Core Viewpoint - The quality management team of Shaanxi Buchang Pharmaceutical, a subsidiary of Buchang Pharmaceutical (603858), won the first prize at the 46th China Pharmaceutical Quality Management Association QC team release conference, highlighting the company's strong foundation and excellence in quality management [1]. Group 1 - The Shaanxi Buchang Pharmaceutical QC team has cultivated a group of outstanding quality management team leaders, providing solid support for the implementation of projects [1]. - Since its establishment in 2019, the QC team has consistently aimed for "continuous improvement in quality management" and has made steady progress [1].

Group 1 - The article highlights the achievements of Zhao Buchang in the field of traditional Chinese medicine, particularly his contributions to the development of innovative products like brain-heart capsules and stable heart granules [2][4] - It emphasizes the ambition for high-quality development in traditional Chinese medicine, focusing on scientific, clinical, preventive, and economic values to support a healthy China [4][5] - The narrative reflects a commitment to delivering quality medicine to the public and leveraging high technology to enhance the traditional medicine industry, showcasing a vision for the future of Chinese medicine [5] Group 2 - The article mentions the "Step Chang Pharmaceutical 75 Blueprint," indicating a strategic plan for the company's future growth and expansion in the global market [4] - It underscores the importance of addressing cardiovascular diseases through the "brain-heart co-treatment" approach, marking a new era in healthcare [5]

Core Points - The company announced a change of address for its subsidiary, Jinan Buchang Caigan Trading Co., Ltd. [1][2] - The board of directors approved the address change with unanimous support during a meeting held on October 20, 2025 [1] - The new address is located at Century City, No. 1, Shijicheng Road, Laiwu High-tech Zone, Jinan City, Shandong Province [1] - The chairman and president are authorized to handle all procedures related to the address change [1] - The address change is not expected to have any adverse impact on the company or its subsidiaries [2]